Skip to content

13F-HR filed by Aisling Capital Management LP

Aisling Capital Management LP filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-13, with 13 holding rows worth $288,452,198.

Accession
0001766721-25-000003
Filed
2025-05-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2025

A holdings report, 13 entries on the cover page, a total value of $288,452,198 stated on the cover page (in dollars after the unit check, H1), rows summing to $288,452,197 with VALUE read as dollars as filed, 13F file number 028-19070. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BRIDGEBIO PHARMA INC10806X102COM6,068,125$209,775,081dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS615,352$39,068,698dollars as filed
SYNDAX PHARMACEUTICALS INC87164F105COM1,025,000$12,587,000dollars as filed
BICARA THERAPEUTICS INC055477103COM568,919$7,413,015dollars as filed
MONTE ROSA THERAPEUTICS INC61225M102COM1,472,331$6,831,616dollars as filed
NUVATION BIO INC COM CL A67080N101Stock2,541,009$4,472,176dollars as filed
COMPASS PATHWAYS PLC20451W101SPONSORED ADS1,198,418$3,427,475dollars as filed
BIOMEA FUSION INC09077A106CMN798,757$1,701,352dollars as filed
CALCIMEDICA INC38942Q202COM NEW521,114$995,328dollars as filed
ELEVATION ONCOLOGY INC COM28623U101Stock2,834,910$734,525dollars as filed
ACLARIS THERAPEUTICS INC COM00461U105Stock434,455$664,716dollars as filed
MARKER THERAPEUTICS INC57055L206COM NEW325,370$400,205dollars as filed
ONKURE THERAPEUTICS INC68277Q105COM CL A88,607$381,010dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001766721-25-000003this filing2025-05-13acceptance time not in the bulk data set